1)
国立がん研究センターがん情報サービス: 全国がん登録
罹患数・率
[Internet] URL: https://www.e-stat.go.jp/statsearch/files?page=1&layout=datalist&toukei=00450173&tstat=000001133323
&cycle=7&tclass1=000001133363&tclass2=000001133366&stat_infid=00003186
7574. 2016.
2)
厚生労働省: 希少がんの定義 [Internet] URL:
https://www.mhlw.go.jp/file/05-Shingikai-10901000-KenkoukyokuSoumuka/0000084713.pdf. 2015.
3)
Higashi T, Nakamura F, Shibata A, et al.: The national database of
hospital-based cancer registries: a nationwide infrastructure to
support evidence-based cancer care and cancer control policy in Japan.
Jpn J Clin Oncol 44(1): 2-8, 2014.
4)
国立がん研究センターがん対策センター: がん診療連携拠点病院の院内がん登
録2018年集計報告 [Internet] URL:
https://ganjoho.jp/data/reg_stat/statistics/brochure/2018_report.pdf.
2019.
5)
Nieminen M, Aro K, Jouhi L, et al.: Causes for delay before specialist
consultation in head and neck cancer. Acta Oncol 57(12): 1677-1686,
2018.
6)
Department of Veterans Affairs Laryngeal Cancer Study Group: Induction
chemotherapy plus radiation compared with surgery plus radiation in
93
patients with advanced laryngeal cancer. N Engl J Med 324(24): 16851690, 1991.
7)
Pignon JP, Bourhis J, Domenge C, et al.: Chemotherapy added to
locoregional treatment for head and neck squamous-cell carcinoma:
three meta-analyses of updated individual data. MACH-NC Collaborative
Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet
355(9208): 949-955, 2000.
8)
Yagishita A, Fujii S, Yano T, et al.: Endoscopic findings using
narrow-band imaging to distinguish between basal cell hyperplasia and
carcinoma of the pharynx. Cancer Sci 105(7): 857-861, 2014.
9)
日本頭頸部癌学会: 頭頸部癌取扱い規約（第5版）, 2012.
10)
National Cancer Institute Surveillance, Epidemiology, and End Results
Program: Overview of the SEER Program [Internet] URL:
https://seer.cancer.gov/about/overview.html. 2010.
11)
U.S. Department of Health and Human Services: About the SEER Program
[Internet] URL: https://seer.cancer.gov/about/
12)
The Surveillance Research Program: Number of Persons by Race and
Hispanic Ethnicity for SEER Participants (2010 Census Data) [Internet]
URL:
13)
https://seer.cancer.gov/registries/data.html. 2010.
American College of Surgeons: About the National Cancer Database
[Internet] URL: https://www.facs.org/qualityprograms/cancer/ncdb/about
94
14)
厚生労働省: がん診療連携拠点病院等の整備に関する指針 [Internet] URL:
https://www.mhlw.go.jp/content/000347080.pdf. 2018.
15)
Watanabe A, Taniguchi M, Tsujie H, et al: The value of narrow band
imaging for early detection of laryngeal cancer. Eur Arch
Otorhinolaryngol 266(7): 1017-1023, 2009.
16)
Muto M, Takahashi M, Ohtsu A, et al: Risk of multiple squamous cell
carcinomas both in the esophagus and the head and neck region.
Carcinogenesis 26(5): 1008-1012, 2005.
17)
遠藤光男: 早期食道癌ー全国集計の分析ー. Gastroenterological Endoscopy
32(10), 1990.
18)
Ozawa S, Tachimori Y, Baba H, et al: Comprehensive Registry of
Esophageal Cancer in Japan, 2002. Esophagus 7(1): 7-22, 2010.
19)
Tachimori Y, Ozawa S, Numasaki H, et al: Comprehensive Registry of
Esophageal Cancer in Japan, 2009. Esophagus 13: 110-137, 2016.
20)
Kinjo, Y, Nonaka, S, Oda, I, et al: The short-term and long-term
outcomes of the endoscopic resection for the superficial pharyngeal
squamous cell carcinoma. Endosc Int Open 3(4): E266-E273, 2015.
21)
Muto M, Satake H, Yano T, et al: Long-term outcome of transoral organpreserving pharyngeal endoscopic resection for superficial pharyngeal
cancer. Gastrointest Endosc 74: 477-484, 2011.
95
22)
Satake H, Yano T, Muto M, et al: Clinical outcome after endoscopic
resection for superficial pharyngeal squamous cell carcinoma invading
the subepithelial layer. Endoscopy 47(1): 11-18, 2014.
23)
Kaneko K, Yano T, Minashi K, et al: Clinical study treatment strategy
for superficial pharyngeal squamous cell carcinoma synchronously
combined with esophageal cancer. Oncology 84(1): 57-64, 2012.
24)
Tokumaru Y, Fujii M, Yane K, et al.: Human papillomavirus in
oropharyngeal squamous cell carcinoma-A multicenter prospective study
in Japan. Jpn J Head Neck Cancer 37: 398-404, 2011.
25)
Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and
rising oropharyngeal cancer incidence in the United States. J Clin
Oncol 29(32): 4294-4301, 2011.
26)
D'Souza G, Kreimer AR, Viscidi R, et al: Case-control study of human
papillomavirus and oropharyngeal cancer. N Engl J Med 356(19): 19441956, 2007.
27)
Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival
of patients with oropharyngeal cancer. N Engl J Med 363(1): 24-35,
2010.
28)
Fakhry C, Gillison ML: Clinical implications of human papillomavirus
in head and neck cancers. J Clin Oncol. 24(17): 2606-2011, 2006.
29)
Kalyani S, Ryan S, Elizabeth YC, et al.: Oral Human Papillomavirus
Infection: Differences in Prevalence Between Sexes and Concordance
96
With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Ann
Intern Med 167(10): 714－724, 2017.
30)
日本頭頸部癌学会: 頭頸部癌診療ガイドライン
2018年版, 2018.
31)
Karsten JJ, Peter CG: Overdiagnosis in publicly organised mammography
screening programmes: systematic review of incidence trends. BMJ 339:
2587, 2009.
32)
落合淳志: 頭頸部癌の病理. 日本耳鼻咽喉科学会会報 113(6): 535-541,
2010.
33)
藤井誠志、砂川弘憲、門田智裕: 食道・頭頸部表在性扁平上皮癌の病理診断.
日本消化器病学会雑誌 115(10): 862-867, 2018.
34)
日本頭頸部癌学会表在癌委員会: 頭頸部表在癌取扱い指針, 2018.
35)
斉川雅久, 福田諭, 永橋立望, 他: 統計からみた頭頸部多重がんの実態. 頭頸
部腫瘍 29(4) 526－540, 2003.
36)
日本食道学会: 食道癌診断・治療ガイドライン, 2012.
37)
Watanabe A, Hosokawa M, Taniguchi M, et al.: Head and neck cancer
associated with esophageal cancer. Auris Nasus Larynx 34(2): 207-211,
2006.
38)
Muto M, Nakane M, Katada C: Squamous cell carcinoma in situ at
oropharyngeal and hypopharyngeal mucosal sites. Cancer 101(6): 13751381, 2004.
39)
Gono K, Yamazaki K, Doguchi N, et al: Endoscopic Observation of Tissue
by Narrowband Illumination. Optical Review 10: 211-215, 2003.
97
40)
北村陽子，小山恒男，友利彰寿, 他: NBI による早期食道癌診断white light
とnarrow band imagingを用いた非拡大内視鏡検査による早期食道癌診断の
sensitivity. 胃と腸 43(10): 1453－1461, 2008.
41)
Yano T, Kaneko K, Minashi K, et al: Observation technique and
diagnosis for superficial cancer in the head and neck field during
upper gastrointestinal endoscopy. Gastroenterological Endoscopy 52:
1440-1450, 2010.
42)
Nonaka S, Saito Y: Endoscopic diagnosis of pharyngeal carcinoma by
NBI. Endoscopy 40(4): 347-351, 2008.
43)
渡邉昭仁，谷口雅信: 下咽頭癌診断の進歩
内視鏡による早期発見. JOHNS
29(6): 963-966, 2013.
44)
Rikitake R, Ando M, Higashi T, et al.: Current status of superficial
pharyngeal squamous cell carcinoma in Japan. Int J Clin Oncol 22(5):
826-833, 2017.
45)
Tony JW, Nadeem R, Simon KC, et al.: Intensity-modulated radiation
therapy for nasopharyngeal carcinoma: a review. Journal of Radiation
Oncology 1: 129-146, 2012.
46)
Nishimura Y, Nakamatsu K, Shibata T, et al: Importance of the initial
volume of parotid glands in xerostomia for patients with head and neck
cancers treated with IMRT. Japanese Journal of Clinical Oncology
35(7): 375-379, 2005.
98
47)
Yang H, Chen X, Lin S, et al.: Treatment outcomes after reduction of
the target volume of intensity-modulated radiotherapy following
induction chemotherapy in patients with locoregionally advanced
nasopharyngeal carcinoma: a prospective, multi-center, randomized
clinical trial. Radiother Oncol 126(1): 37-42, 2018.
48)
Zhang B, Mo Z, Du W, et al.: Intensity-modulated radiation therapy
versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma:
A systematic review and meta-analysis. Oral Oncology 51(11): 10411046, 2015.
49)
Staffurth J, Radiotherapy Development Board: A review of the clinical
evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll
Radiol) 22(8): 643-657, 2010.
50)
Veldeman L, Madani I, Hulstaert F, et al.: Evidence behind use of
intensity-modulated radiotherapy: a systematic review of comparative
clinical studies. Lancet Oncol 9(4): 367-375, 2008.
51)
Williams M. V, Cooper T, Mackay R, et al.: The implementation of
intensity-modulated radiotherapy in the UK. Clin Oncol (R Coll Radiol)
22(8): 623-628, 2010.
52)
Suh YG, Lee CG, Kim H, et al.: Treatment outcomes of intensity‐
modulated radiotherapy versus 3D conformal radiotherapy for patients
with maxillary sinus cancer in the postoperative setting. Head Neck
38(Suppl1): E207-E213, 2016.
99
53)
日本放射線腫瘍学会: 放射線治療計画ガイドライン
第4版, 2016.
54)
Mell LK, Mehrotra AK, Mundt AJ: Intensity-modulated radiation therapy
use in the U.S., 2004. Cancer 104(6): 1296-1303, 2005.
55)
Society and College of Radiographers Institute of Physics and
Engineering in Medicine Royal College of Radiologists: Intensity
Modulated Radiotherapy (IMRT) in the UK Current access and predictions
of future access rates 2015, 2015.
56)
Frenzel T, Krüll A: The use of IMRT in Germany. Strahlenther Onkol.
191(11): 821-826, 2015.
57)
Mell LK, Roeske JC, Mundt AJ: A survey of intensity-modulated
radiation therapy use in the United States. American Cancer Society
98(1): 204-211, 2003.
58)
Cancer Quality Council of Ontario: Maggiotto C. Backgrounder - Cancer
System Quality Index 2015 [Internet] URL:
http://www.cqco.ca/common/pages/UserFile.aspx?fileId=340715, 2015.
59)
Ministry of Health, Labor and Welfare: [Internet] URL:
http://www.mhlw.go.jp/file/05-Shingikai-10901000-KenkoukyokuSoumuka/0000127460.pdf, 2016.
60)
Japanese Society for Radiation Oncology: Japanese Structure Survey of
Radiation Oncology in 2012. J Radiat Res 61(1): 146-160, 2020.
61)
日本泌尿器科学会: 前立腺がん診療ガイドライン2016年版, 2016.
100
62)
Lai SZ, Li WF, Chen L, et al.: How does intensity-modulated
radiotherapy versus conventional two-dimensional radiotherapy
influence the treatment results in nasopharyngeal carcinoma patients?
Int J Radiat Oncol Biol Phys 80(3): 661–668, 2011.
63)
Zhang L, Zhao C, Ghimire B, et al.: The role of concurrent
chemoradiotherapy in the treatment of locoregionally advanced
nasopharyngeal carcinoma among endemic population: a meta-analysis of
the phase III randomized trials. BMC Cancer 10: 558, 2010.
64)
Caponigro F, Longo F, Ionna F, et al.: Treatment approaches to
nasopharyngeal carcinoma: a review. Anticancer Drugs 21(5): 471-477,
2010.
65)
Chen Y, Sun Y, Liang SB, et al.: Progress report of a randomized trial
comparing long-term survival and late toxicity of concurrent
chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone
in patients with stage III to IVB nasopharyngeal carcinoma from
endemic regions of China. Cancer 119(12): 2230–2238, 2013.
66)
Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Semin
Cancer Biol 12(6): 431-441, 2002.
67)
Lee AW, Lin JC, Ng WT: Current management of nasopharyngeal cancer.
Semin Radiat Oncol 22: 233-244, 2012.
68)
Lee AW, Poon YF, Foo W, et al.: Retrospective analysis of 5037
patients with nasopharyngeal carcinoma treated during 1976-1985:
101
overall survival and patterns of failure. Int J Radiat Oncol Biol Phys
23(2): 261-270, 1992.
69)
He X, Ye M, Guo X, et al.: Treatment outcome of patients with stages
I-II nasopharyngeal carcinoma after late course accelerated
hyperfractionation radiotherapy alone. Oral Oncol 48(10): 1058–1063,
2012.
70)
Blanchard P, Lee A, Marguet S, et al.: Chemotherapy and radiotherapy
in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis.
Lancet Oncol 16(6): 645–655, 2015.
71)
Sun Y, Li WF, Chen NY, et al.: Induction chemotherapy plus concurrent
chemoradiotherapy versus concurrent chemoradiotherapy alone in
locoregionally advanced nasopharyngeal carcinoma: a phase 3,
multicentre, randomised controlled trial. The Lancet Oncology 17(11)
1509-1520, 2016.
72)
Mao YP, Xie FY, Liu LZ, et al.: Re-evaluation of 6th edition of AJCC
staging system for nasopharyngeal carcinoma and proposed improvement
based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys
73(5): 1326–1334, 2009.
73)
Chen L, Hu CS, Chen XZ, et al.: Concurrent chemoradiotherapy plus
adjuvant chemotherapy versus concurrent chemoradiotherapy alone in
patients with locoregionally advanced nasopharyngeal carcinoma: a
102
phase 3 multicentre randomised controlled trial. Lancet Oncol 13(2):
163-171, 2012.
74)
Chen Q-Y, Wen Y-F, Guo L, et al.: Concurrent chemoradiotherapy vs
radiotherapy alone in stage II nasopharyngeal carcinoma: phase III
randomized trial. J Natl Cancer Inst 103(23): 1761–1770, 2011.
75)
Langendijk JA, Leemans CR, Buter J, et al.: The additional value of
chemotherapy to radiotherapy in locally advanced nasopharyngeal
carcinoma: a meta-analysis of the published literature. J Clin Oncol
22(22): 4604–4612, 2004.
76)
Pow EHN, Kwong DLW, McMillan AS, et al.: Xerostomia and quality of
life after intensity-modulated radiotherapy vs. conventional
radiotherapy for early-stage nasopharyngeal carcinoma: Initial report
on a randomized controlled clinical trial. Int J Radiat Oncol Biol
Phys 66(4): 981-991, 2006.
77)
Kam MK, Leung SF, Zee B, et al.: Prospective randomized study of
intensity-modulated radiotherapy on salivary gland function in earlystage nasopharyngeal carcinoma patients. J Clin Oncol 25(31): 48734879, 2007.
78)
日本放射線腫瘍学会、日本医学放射線学会、高精度外部放射線治療研究会: 強
度変調放射線治療（IMRT）ガイドライン, 2008.
103
79)
西尾禎治，芦野靖夫，大西洋，他: 放射線治療における医学物理士・放射線治
療品質管理士に関するアンケート調査結果報告. The Journal of JASTRO
20(1): 29-35, 2008.
80)
国枝悦夫: 高精度放射線治療と IMRT の応用. Radioisotopes 66(5): 201206, 2017.
81)
厚生労働省: 特掲診療科の施設基準等及びその届出に関する手続きの取扱いに
ついて. 保医発0305第3号, 2020.
82） 厚生労働省健康局がん・疾病対策課: がん診療連携拠点病院等における現況報
告について [Internet] URL: https://www.mhlw.go.jp/file/05-Shingikai10901000-Kenkoukyoku-Soumuka/0000194178.pdf, 2014.
83)
Higashi T, Nakamura F, Saruki N, Sobue T.: Establishing a quality
measurement system for cancer care in Japan. Jpn J Clin Oncol 43(3):
225-232, 2013.
84)
Yasunaga H, Matsui H, Horiguchi H, et al.: Clinical Epidemiology and
Health Services Research using the Diagnosis Procedure Combination
Database in Japan. Asian Pacific Journal of Disease Management 7(1-2):
19-24, 2015.
85)
国立がん研究センターがん対策情報センター: がん情報サービス
病院を探す
[Internet] URL: https://hospdb.ganjoho.jp/kyotendb.nsf/xpTopPage.xsp
86)
Japan Society for Head and Neck Cancer Cancer Registry Committee:
Report of Head and Neck Cancer Registry of Japan Clinical Statistics
104
of Registered Patients, 2016. Japan Society for Head and Neck Cancer,
2019.
87)
Mell LK, Roeske JC, Mundt AJ: A survey of intensity-modulated
radiation therapy use in the United States. Cancer 98(1): 204-211,
2003.
88)
国立がん研究センターがん情報サービス「がん登録・統計」（全国がん登録）
全国がん登録
罹患数・率 [Internet] URL: https://www.e-
stat.go.jp/statsearch/files?page=1&layout=datalist&toukei=00450173&tstat=000001133323
&cycle=7&tclass1=000001133363&tclass2=000001133366&stat_infid=00003186
7574, 2016.
89)
Lee N, Puri DR, Blanco AI, Chao KSC: Intensity-modulated radiation
therapy in head and neck cancers: an update. Head Neck 29(4): 387-400,
2007.
90)
Vora SA, Wong WW, Schild SE, et al.: Analysis of biochemical control
and prognostic factors in patients treated with either low-dose threedimensional conformal radiation therapy or high-dose intensitymodulated radiotherapy for localized prostate cancer. Int J Radiat
Oncol Biol Phys 68(4): 1053-1058, 2007.
91)
Zelefsky MJ, Levin EJ, Hunt M, et al.: Incidence of late rectal and
urinary toxicities after three-dimensional conformal radiotherapy and
105
intensity-modulated radiotherapy for localized prostate cancer. Int J
Radiat Oncol Biol Phys 70(4): 1124-1129, 2008.
92)
Boero IJ, Paravati AJ, Xu B, et al.: Importance of Radiation
Oncologist Experience Among Patients With Head-and-Neck Cancer Treated
With Intensity-Modulated Radiation Therapy. J Clin Oncol 34(7): 684690, 2016.
93)
Peters LJ, O'Sullivan B, Giralt J, et al.: Critical impact of
radiotherapy protocol compliance and quality in the treatment of
advanced head and neck cancer: results from TROG 02.02. J Clin Oncol
28(18): 2996-3001, 2010.
94)
Johansson KA, Nilsson P, Zackrisson B, et al.: The quality assurance
process for the ARTSCAN head and neck study - A practical interactive
approach for QA in 3DCRT and IMRT. Radiotherapy and Oncology 87(2):
290-299, 2008.
95)
Rikitake R, Tsukada Y, Higashi T, et al.: Use of intensity-modulated
radiation therapy for nasopharyngeal cancer in Japan: analysis using a
national database. Jpn J Clin Oncol 49(7): 639-645, 2019.
96)
日本がん治療認定医機構 [Internet] URL:
https://www.jbct.jp/Portals/0/Linkdata/History/JBCT10thAnniv_chronolog
y(no-page)_180611_sec.pdf, 2007.
97)
日本頭頚部外科学会: 指定研修施設一覧 [Internet] URL:
https://jshns.org/?page_id=938, 2019.
106
98)
日本頭頸部外科学会: 頭頸部がん専門医制度認定施設資格条件 [Internet]
URL: https://jshns.org/?page_id=1056, 2009.
99)
日本頭頸部癌学会: 頭頸部癌診療ガイドライン, 2013.
100) 中川尚志、熊本芳彦、名取良弘: 聴器癌の治療選択ー手術療法の適応と限界
ー. 耳鼻と臨床 53（補1）: S41-S47, 2007.
101) Shinomiya H, Yamashita D, Ejima Y, et al.: Concomitant
Chemoradiotherapy for Advanced Squamous Cell Carcinoma of the Temporal
Bone. Head Neck 38: E949-953, 2016.
102) Shiga K, Saitoh D, Ogawa T, et al.: Long-Term Outcomes of Patients
with Squamous Cell Carcinoma of the Temporal Bone after Concomitant
Chemoradiotherapy. J Neurol Surg B Skull Base 79: S316-321, 2018.
103) Nichole RD, Hilliary NW, Dale SC, et al.: Outcomes Following Temporal
Bone Resection. Laryngoscope 120(8): 1516-1522, 2010.
104) Lukas A, Mohamed S, Marco D, et al.: Long-term functional outcome
after laryngeal cancer treatment. Radiation Oncology 14(1): 101, 2019.
105) Zenda S, Onozawa Y, Tahara M, et al.: Feasibility study of single
agent Cisplatin and concurrent radiotherapy in Japanese patients with
squamous cell carcinoma of the head and neck: preliminary results. Jpn
J Clin Oncol 37(10): 725-729, 2007.
106) 松浦一登, 嵯峨井俊, 片桐克則, 他: 頭頸部外科医が行う化学放射線療法: そ
の有効性と安全性. 頭頸部癌 37(4): 454-459, 2011.
107
107) Kiyota N, Tahara M, Okano S, et al.: Phase II feasibility trial of
adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese
patients with post-operative high-risk squamous cell carcinoma of the
head and neck. Jpn J Clin Oncol 42(10): 927-933, 2012.
108) 丹生健一: 頭頸部がん専門医制度の将来展望. 頭頸部外科 21(1): 1-4, 2011.
109) Japan Society for Head and Neck Cancer Cancer Registry Committee:
Report of Head and Neck Cancer Registry of Japan Clinical Statistics
of Registered Patients, 2015, 2017.
110) 日本頭頸部癌学会: 頭頸部悪性腫瘍登録事業
症例登録施設
[Internet]
URL:
http://www.jshnc.umin.ne.jp/pdf/20171201optout_tourokushisetsu_2016.pd
f, 2016.
111) 丹生健一, 中溝宗永, 吉本世一, 他: 頭頸部癌全国症例登録システムの構築と
臓器温存治療のエビデンス創出. 日本耳鼻咽喉科学会会報 122(3): 202-203,
2019.
112) James A. Bonner MD, Paul M, et al.: Radiotherapy plus Cetuximab for
SquamousCell Carcinoma of the Head and Neck. N Engl J Med 354(6): 567578, 2006.
113) K KA, Qiang Z, David IR, et al.: Randomized Phase III Trial of
Concurrent Accelerated Radiation Plus Cisplatin With or Without
Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. J
Clin Oncol 32(27): 2940-2950, 2014.
108
114) Yungan T, Anne A, Christian S, et al.: Improved Outcome by Adding
Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally
Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase
III Randomized Trial. J Clin Oncol 36(31), 2018.
109
...
論文の公開元へ
